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Objectives: Portal hypertension has been reported as a negative prognostic factor and a relative
contraindication for liver resection. This study considers a possible role of fibrosis evaluation by transient
elastography (FibroScan®) and its correlation with portal hypertension in patients with cirrhosis, and
discusses the use of this technique in planning therapeutic options in patients with hepatocellular
carcinoma (HCC).
Methods: A total of 77 patients with cirrhosis, 42 (54.5%) of whom had HCC, were enrolled in this study
during 2009–2011. The group included 46 (59.7%) men. The mean age of the sample was 65.2 years. The
principle aetiology of disease was hepatitis C virus (HCV)-related cirrhosis (66.2%). Liver function was
assessed according to Child–Pugh classification. In all patients liver stiffness (LS) was measured using
FibroScan®. The presence of portal hypertension was indirectly defined as: (i) oesophageal varices
detectable on endoscopy; (ii) splenomegaly (increased diameter of the spleen to12 cm), or (iii) a platelet
count of <100 000 platelets/mm3.
Results: Median LS in all patients was 27.9 kPa. Portal hypertension was recorded as present in 37
patients (48.1%) and absent in 40 patients (51.9%). Median LS values in HCC patients with and without
portal hypertension were 29.1 kPa and 19.6 kPa, respectively (r = 0.26, P < 0.04). Liver stiffness was used
to implement the Barcelona Clinic Liver Cancer algorithm in decisions about treatment.
Conclusions: The evaluation of liver fibrosis by transient elastography may be useful in the follow-up of
patients with cirrhosis and a direct correlation with portal hypertension may aid in the evaluation of
surgical risk in patients with HCC and in the choice of alternative therapies.
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Introduction
Underlying liver cirrhosis is the strongest predisposing factor for
hepatocellular carcinoma (HCC) and is found in 80% of HCC
patients.1 However, up to 40% of HCC patients are suitable for
consideration for potentially curative interventions. Excluding
liver transplantation, which may resolve both conditions, the
treatment of HCC and cirrhosis is complex because of the simul-
taneous needs for radical oncological treatment and the preserva-
tion of hepatic parenchyma. In patients with HCC and underlying
cirrhosis, the correct estimation of the future hepatic reserve is
crucial to ensure patients are correctly selected for surgical resec-
tion.2,3 The Barcelona Clinic Liver Classification (BCLC) scheme
is considered the most used staging system and therapeutic
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algorithm for patients with HCC; however, in this classification
portal hypertension and increased bilirubin are contraindications
for liver resection, but the severity of portal hypertension is only
indirectly defined.1 Portal hypertension and hepatic fibrosis are
generally considered poor prognostic factors in patients with
HCC undergoing liver resection4 and the pathophysiology of liver
fibrosis and portal hypertension are directly correlated.5 In fact,
the initial event in portal hypertension is increased vascular resis-
tance to portal flow, primarily caused by structural changes such
as fibrotic scar tissue and regenerative nodules that compress
portal and central venules in which stellate cells are involved in the
regulation of the liver microcirculation and portal hypertension.5
Transient elastography (FibroScan®; Echosens SA, Paris,
France) is a non-invasive method that uses measurements of liver
stiffness (LS) to assess hepatic fibrosis in patients with chronic
liver disease. It is easily performed, gives immediate results and
has good reproducibility. A mechanical pulse is generated at the
skin surface and is propagated through the liver. The velocity of
the wave is measured by ultrasound (US). The velocity is directly
correlated to the stiffness of the liver, which, in turn, reflects the
degree of fibrosis.6 The aim of this study was to investigate the
relationship between LS as a surrogate measure of hepatic fibrosis
and portal hypertension.4,7,8
Materials and methods
The current study enrolled patients with cirrhosis between
November 2009 and August 2011. Patients with portal vein
thrombosis were excluded from the study. Data were collected on
age, sex, disease aetiology, liver function, presence of portal
hypertension, Model for End-stage Liver Disease (MELD) score,
alpha-fetoprotein values and tumour characteristics (single or
multi-nodular HCC). Cirrhosis diagnoses were based on clinical,
laboratory and US findings.9 Liver function was assessed using the
Child–Pugh classification. The presence of portal hypertension
was indirectly defined according to current guidelines as: (i)
oesophageal varices detectable on endoscopy; (ii) splenomegaly
(increased diameter of the spleen to 12 cm), or (iii) a platelet
count of <100 000 platelets/mm3.10 Direct measurements of the
hepatic venous pressure gradient (HVPG) were not performed in
this series. In all patients, LS was measured using FibroScan® 502
in the right lobe of the liver, through the intercostal space, with the
patient lying in the dorsal position and the right arm in maximal
abduction. The tip of the transducer probe was covered with
coupling gel and placed on the skin between the ribs at the level of
the right lobe of the liver.
In patients with HCC, sonographic evaluation was used to
assess non-tumour liver parenchyma before FibroScan® LS values
were obtained. Ten validated measurements were obtained in each
patient. The success rate was calculated as the number of validated
measurements divided by the total number of measurements. The
results were expressed in kilopascals (kPa).A success rate of60%
and an interquartile range (IQR) of 20–30% of the median
value were considered reliable.6 Liver stiffness was considered as
absent or mild for LS values of 0.0–7.0 kPa; LS values of >12.5 kPa
were considered indicators of cirrhosis.11 Liver stiffness values of
12.5–17.6 kPa were considered to represent low–moderate LS and
values of >17.6 kPa were considered to indicate high LS, in line
with Vizzutti et al.12
Possible relationships among LS value, portal hypertension,
Child–Pugh class and MELD score were evaluated.
Statistical analysis
Quantitative data are given as the median and IQR. Qualitative
data are given in percentages. Differences between the groups
(with and without HCC, respectively) were tested using the sign
test for quantitative data and chi-squared test (or Fisher’s exact
test, as appropriate) for qualitative data. The association between
LS and portal hypertension was evaluated using the Wilcoxon
two-sample test. The association between LS and Child–Pugh
class was tested using the Kruskall–Wallis test. Correlations
between quantitative variables were computed using Spearman’s
correlation test. Boxplots were furnished to illustrate median and
IQR LS values according to portal hypertension and Child–Pugh
class.
Results
The current study enrolled 77 patients with cirrhosis, 42 (54.5%)
of whom had HCC, between November 2009 and August 2011.
The mean age of the patient cohort was 65.2 years (range: 45–86
years) and the group included 46 (59.7%) men. Demographics,
underlying aetiology, level of hepatic dysfunction and tumour
characteristics are shown in Table 1. The presence of portal hyper-
tension according to Child–Pugh class and tumour characteristics
in HCC patients is shown in Table 2.Median LS in all patients was
27.9 kPa (IQR 19.8–31.5 kPa), confirming severe fibrosis (F4,
Metavir score 4, Ishak score 5–6).Median LS in HCC patients with
portal hypertension (29.1 kPa, IQR 19.1–39.3 kPa) was higher
than that in patients without portal hypertension (19.6 kPa, IQR
14.9–32.5 kPa) (r = 0.28, P < 0.04) (Fig. 1). A direct correlation
between LS and Child–Pugh class was found: patients in Child–
Pugh classes B and C presented the highest levels of LS (P < 0.005)
(Fig. 2). However, LS measurements correlated with MELD
scores: the median LS value in patients with MELD scores of >10
was 29.1 kPa, whereas that in patients with MELD scores of 10
was 22.9 kPa (r = 0.26, P = 0.02) (Fig. 3).
Treatment decisions were evaluated according to the BCLC
algorithm and LS was used to provide a better evaluation of portal
hypertension and to predict surgical risk. In this series, of 20
patients with Child–Pugh class A status with a single HCC, eight
patients were submitted to liver resection, nine to radiofrequency
ablation and three to percutaneous ethanol injection (Table 3).
Patients who underwent liver resection presented normal biliru-
bin values, MELD scores of <10, performance status of 0–1 and
Okuda stage I. Four patients displayed no portal hypertension,
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low–moderate LS and no associated diseases. The other four
patients presented with mild or severe portal hypertension, but
low–moderate LS. In patients who underwent surgical resection,
histological analysis of six specimens demonstrated a direct cor-
relation between FibroScan® data and fibrosis grading. In two
specimens the histological grade of cirrhosis did not correlate
with FibroScan® data. In these patients, transient elastography
underestimated the degree of liver cirrhosis. In the 24 patients
with Child–Pugh class B or C status and with multinodular HCC,
chemoembolization or systemic therapies were administered. In
the surgical group, morbidity occurred in two patients (25.0%),
with no mortality. Patients with oesophageal varices at high risk
for rupture were treated with endoscopic sclerosis before surgery.
Discussion
The pathophysiology of fibrosis and portal hypertension are
directly correlated; hepatic stellate cells (HSC) are involved in the
regulation of liver microcirculation and portal hypertension.5 In
fact, activated HSC have the ability to contract or relax in response
to a number of vasoactive substances.5 Activated cells are charac-
terized by loss of vitamin A droplets, increased proliferation,
release of proinflammatory, profibrogenic and promitogenic
cytokines, migration to sites of injury, increased production of
extracellular matrix components, and alterations in the matrix
protease activity that provides the fundamental materials for
Table 1 General characteristics of patients
Patients
with
cirrhosis
P-value Patients
with
cirrhosis
and HCC
Patients, n 35 42
Age, years, median 60.8 <0.001 69.1
Sex, n (%)
Male 19 (54.3%) 27 (64.3%)
Female 16 (45.7%) 0.37 15 (35.7%)
Aetiology, n (%)
Hepatitis C virus 23 (65.7%) 28 (66.7%)
Hepatitis B virus 1 (2.9%) 8 (19.1%)
Alcohol-related 3 (8.6%) –
HBV–HDV co-infections 1 (2.9%) 1 (2.4%)
Other aetiology 7 (19.9%) 5 (11.9%)
Child–Pugh class, n (%)
Child–Pugh class A 30 (85.7%) 30 (71.4%)
Child–Pugh class B 3 (8.6%) 0.23 10 (23.8%)
Child–Pugh class C 2 (5.7%) 2 (4.8%)
Portal hypertension, n (%)
Yes 11 (31.4%) 0.008 26 (61.9%)
Oesophageal varices, n (%) 6 (54.5%) 16 (61.5%)
Grade I 3 (50.0%) 10 (62.5%)
Grade II 2 (33.3%) 3 (18.8%)
Grade III 1 (16.7%) 3 (18.8%)
Spleen diameter 12 cm
+ PC <100 000
platelets/mm3
5 (45.5%) 10 (38.5%)
No 24 (68.6%) 16 (38.1%)
MELD score, n (%)
10 30 (85.7%) 30 (71.4%)
>10 5 (14.3%) 12 (28.6%)
Alpha-fetoprotein, n (%)
<20 ng/ml – 24 (57.1%)
>200 ng/ml – 18 (42.9%)
Tumour characteristics, n (%)
Single – 28 (66.7%)
Multinodular – 14 (33.3%)
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HDV, hepatitis D
virus; MELD, Model for End-stage Liver Disease; PC, platelet count.
Table 2 Patients with hepatocellular carcinoma (HCC) were classi-
fied according to tumour characteristics (single or multinodular),
Child–Pugh classification and presence of portal hypertension
Single HCC Multinodular
HCC
Patients, n 28 14
Child–Pugh classification, n (%)
Child–Pugh class A 20 (71.4%) 10 (71.4%)
With portal hypertension 14 7
Without portal hypertension 6 3
Child–Pugh class B 6 (21.4%) 3 (21.4%)
With portal hypertension 6 3
Without portal hypertension – –
Child–Pugh class C 2 (7.1%) 1 (7.1%)
With portal hypertension 2 1
Without portal hypertension – –
No
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Figure 1 Median liver stiffness in patients with hepatocellular carci-
noma was higher in patients with than without portal hypertension
(29.1 kPa vs. 19.6 kPa; P < 0.04)
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tissue repair.5,13 In acute or self-limiting liver damage, these
changes are transient, whereas in persistent injury they lead to
chronic inflammation and the accumulation of extracellular
matrix, resulting in liver fibrosis and, ultimately, cirrhosis. Several
growth factors and cytokines are involved in HSC activation and
proliferation, of which transforming growth factor-b and platelet-
derived growth factor are probably the most important.13
Preoperative evaluation of the severity of cirrhosis by biopsy of
non-tumorous liver for histological grading of fibrosis or mea-
surement of portal pressure (HVPG) has been advocated by
some authors, but these methods are less practicable because
of the invasiveness of the investigations and are not routinely
performed.8,14–17 The serological markers [ialuronic acid, glyco-
peptides, APRI (aspartate aminotransferase : platelet ratio index)
score] are used only in chronic liver disease and magnetic reso-
nance imaging (MRI) elastography is still being studied.18 There-
fore, at present, transient elastography is considered a valid
method to achieve a more accurate diagnosis of fibrosis and,
indirectly, of portal hypertension in patients with cirrhosis.
However, this method has some limitations: LS measurements can
be difficult to obtain in obese patients and in patients with narrow
intercostal spaces. Failure rates have ranged from 2.4% to 9.4%.6
The reproducibility of transient elastography is another impor-
tant prerequisite for its widespread application in clinical practice.
In a study by Fraquelli et al., in which 800 transient elastography
examinations were performed by two operators in 200 patients
with various chronic liver diseases, reproducibility was found to
be excellent for both inter- and intraobserver agreement, with
intraclass correlation coefficients (ICCs) of 0.984.19 The validity of
LS results also depends on two important parameters: IQR and
success rate. However, although a success rate of 60% is recom-
mended, no study has yet achieved this in relation to the use of
FibroScan® for the diagnosis of liver fibrosis.6 In some situations,
transient elastography can underestimate liver cirrhosis and its
accuracy requires to be improved. Vizzutti et al.12 reported a
strong relationship between LS and HVPG measurements in 61
patients (r = 0.81, P < 0.0001), with excellent correlations for
HVPG values of <10 mmHg (r = 0.81, P < 0.0003) and
<12 mmHg (r = 0.91, P < 0.0001), thereby supporting the appli-
cation of the LS measurement as a non-invasive tool for the iden-
tification of chronic liver disease in patients with clinically severe
portal hypertension. De Lédinghen and Vergniol6 also reported a
direct correlation between LS and the presence of oesophageal
varices and the HVPG. Hepatic resection for HCC, mainly
through the improved selection of patients, has become a safe
procedure, even in patients with cirrhosis, and recent large series
have reported good results with significant reductions in postop-
erative mortality (0.0–4.5%), major morbidity (5.6–19.7%) and
liver decompensation.8,15,20,21 In terms of surgery-associated risk,
Bruix et al. have reported that patients with cirrhosis and
increased portal pressure are at high risk for postoperative hepatic
failure and surgical resection should therefore be restricted to
patients without portal hypertension.14 The level of hepatic fibro-
sis is considered a predictor of outcome in patients with HCC.4
Other recent studies have demonstrated that in patients with
Child–Pugh class A status, short-term results are similar in
patients with and without portal hypertension8 and this value is
therefore not an absolute negative predictive risk factor.15 The
current study investigated the role of the LS measurement as a
potential parameter for the more accurate selection of cirrhosis
patients with portal hypertension and HCC. In clinical practice,
decisions on the treatment to be administered to cirrhosis patients
with HCC are based on many factors, including associated dis-
eases, performance status, aetiology, viral activity, hepatic func-
tion (Child–Pugh class and MELD score), and numbers, sizes and
sites of HCC lesions. All these parameters are easily obtained with
biochemical and radiological tests, as are those related to portal
hypertension (platelet count of <100 000 platelets/mm3, splenom-
egaly, oesophageal varices). However, portal hypertension is very
difficult to assess without a direct measurement of HVPG; ‘mild
portal hypertension’ was arbitrarily defined by the presence of a
single parameter, and ‘severe portal hypertension’ was defined
according to the presence of all three parameters. In patients with
cirrhosis, it is also difficult to establish the severity of liver fibrosis,
which is considered a risk factor directly correlated with portal
hypertension. In the current study, the use of transient elastogra-
phy allowed patients to be divided into those with low–moderate
LS (12.5–17.5 kPa) and those with high LS (>17.5 kPa), and estab-
lished a direct, although not very strong (probably as a result of
the small sample size), correlation with portal hypertension
values. The LS measurement was used to complement the scoring
of risk factors within the BCLC algorithm in order to more accu-
rately select patients for surgery. In 20 patients with Child–Pugh
class A status and a single nodule, liver resection was performed in
eight patients (40.0%) with low morbidity and no mortality.
Although the current results do not demonstrate a strong corre-
lation between portal hypertension and LS, it is the authors’ belief
that evaluation of fibrosis using a non-invasive method such as
FibroScan® elastography may have a possible role in decisions on
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Figure 2 A direct correlation between liver stiffness (LS) and Child–
Pugh class was found: patients in Child–Pugh classes B and C
showed the highest LS values (P < 0.005)
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the treatment of patients with cirrhosis and HCC. This potential
role was demonstrated by Kim et al.,22 who reported an LS mea-
surement of 25.6 kPa and an indocyanine green retention rate at
15 min (IGC R15) of 12% as the most accurate cut-off values for
the prediction of postoperative hepatic failure.
Conclusions
Liver stiffness measurements may be used to assess both fibrosis
and portal hypertension in patients with cirrhosis and HCC, and
may lead to the better evaluation of surgical risk in patients with
0
0
10
Li
ve
r 
st
iff
ne
ss
, k
P
a
20
30
40
50
60
70
80
5 10 15 20 25
MELD score
Figure 3 Liver stiffness (LS) measurements correlated with Model for End-stage Liver Disease (MELD) scores: the median LS value in
patients with MELD scores of >10 was 29.07 kPa, whereas the median LS value in patients with MELD scores of 10 was 22.91 kPa
(P < 0.02)
Table 3 Decision making in patients with hepatocellular carcinoma with Child–Pugh class A status with a single tumour according to the
Barcelona Clinic Liver Cancer algorithm and liver stiffness values
Patient Child–Pugh class Bilirubin MELD score PST Okuda stage PHa Liver stiffness AD Treatment
1 A <2.0 <10 0 I No Low–moderate No Resection
2 A <2.0 <10 0 I No Low–moderate No Resection
3 A <2.0 <10 0 I 2 Low–moderate No Resection
4 A <2.0 <10 0 I 1 Low–moderate Diabetes Resection
5 A <2.0 <10 1 I No Low–moderate No Resection
6 A <2.0 <10 1 I No Low–moderate No Resection
7 A 2.2 <10 1 I 2 Low–moderate No Resection
8 A <2.0 <10 0 I 3 Low–moderate No Resection
9 A 2.0 <10 0 I 1 High CVD PEI
10 A 3.0 <10 1 I 2 High CVD PEI
11 A 3.0 <10 1 I 2 High Diabetes, CVD RFA
12 A 2.6 <10 0 I 1 High No RFA
13 A 2.5 <10 1 I 3 High Diabetes PEI
14 A 2.5 <10 0 I 2 High No RFA
15 A <2.0 <10 0 I 2 High No RFA
16 A <2.0 <10 1 I 2 High Diabetes RFA
17 A <2.0 <10 2 I 3 High COPD RFA
18 A 2.4 <10 1 I 2 High CVD RFA
19 A <2.0 <10 2 I 2 High COPD RFA
20 A 2.3 <10 1 I 2 High Diabetes RFA
a1 = oesophageal varices (OV); 2 = OV + splenomegaly (S); 3 = OV + S + platelet count of <100 000 platelets/mm3.
AD, associated diseases; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; MELD, Model for End-stage Liver Disease;
PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; PH, portal hypertension; PST, performance status test.
HPB 407
HPB 2012, 14, 403–408 © 2012 International Hepato-Pancreato-Biliary Association
Child–Pugh class A status. The current data require further elabo-
ration in studies on large numbers of patients undergoing liver
resection.
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